US Patent 11318132 Diversion-resistant opioid formulations
Patent 11318132 was granted and assigned to Elysium Therapeutics, Inc. on May, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Inventor Names
Thomas E. Jenkins0
Edits on 24 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
113181320
Date of Patent
May 3, 2022
0Patent Application Number
163938120
Date Filed
April 24, 2019
0Patent Citations
Patent Primary Examiner
CPC Code
Edits on 22 Mar, 2023
Golden AI
Infobox
Patent Citations
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 19 May, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+543 characters)
US Patent 11318132 Diversion-resistant opioid formulations
Article
The present invention provides a composition comprising an opioid agonist, and a polymer-antagonist conjugate. The polymer-antagonist conjugate preferably does not hydrolyze upon administration to a patient, and does not bind to the opioid receptors. The covalent bond between the polymer and the antagonist in the conjugate is broken over a defined period of time to release the antagonist into the formulation. The released antagonist attenuates the liking of the agonist, thereby eliminating the incentive to the diversion of the medicines.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11318132
Date of patent
May 3, 2022
Patent application number
16393812
Date Filed
April 24, 2019
Patent citations
Patent primary examiner
CPC Code
Find more entities like US Patent 11318132 Diversion-resistant opioid formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.